Can You Take Evenity (Romosozumab) with Zolpidem?

Why There Is No Pharmacokinetic Conflict

Romosozumab is a humanized IgG2 monoclonal antibody that binds sclerostin. Its elimination follows the same pathway as endogenous immunoglobulins: reticuloendothelial proteolysis and target-mediated disposition [1]. It does not undergo hepatic phase I or phase II metabolism. Zolpidem, by contrast, is a small-molecule imidazopyridine metabolized almost entirely by cytochrome P450 3A4, with minor contributions from CYP1A2 and CYP2C9 [2].

Because romosozumab never enters the CYP system, it cannot inhibit, induce, or compete for the enzymes that clear zolpidem. It also has no known interaction with P-glycoprotein or organic anion transporters. The FDA prescribing information for Evenity does not list any contraindicated or cautioned co-medications based on metabolic interference [1]. From a strict pharmacokinetic standpoint, plasma levels of neither drug change when given together.

This is consistent with the broader principle that monoclonal antibodies rarely produce classical drug-drug interactions. A 2020 review in Clinical Pharmacology & Therapeutics confirmed that among 40+ approved therapeutic antibodies, none had clinically meaningful CYP-mediated interactions [3].

The Real Risk: Pharmacodynamic Overlap on Fall Probability

The absence of a kinetic interaction does not mean co-prescribing is risk-free. Patients receiving romosozumab have severe osteoporosis. Their T-scores typically fall at or below -2.5, and many have prior fragility fractures. In this population, a single fall can produce a vertebral compression fracture or hip fracture. Any drug that increases fall probability works against the therapeutic goal of romosozumab.

Zolpidem raises fall risk through multiple mechanisms. A meta-analysis by Tom et al. (2016) in the Journal of the American Geriatrics Society found that Z-drug use was associated with a 2.55-fold increased odds of falls in adults over 65 (95% CI 1.89 to 3.44) [4]. The FDA added a boxed warning to all zolpidem products in 2019 after reports of complex sleep behaviors (sleepwalking, sleep-driving, performing activities while not fully awake) that resulted in serious injuries [2].

Romosozumab itself was not associated with increased fall incidence in the FRAME trial (N=7,180). Fall rates were similar between romosozumab and placebo groups (9.7% vs. 9.6% over 12 months) [5]. The drug does not cause sedation or dizziness at meaningful rates. The concern is entirely about the vulnerability of the patient population, not the drug itself adding CNS depression.

Quantifying the Combined Fall-Fracture Risk

A patient taking romosozumab has severe osteoporosis by definition (the FDA approved it only for patients at high fracture risk). The ARCH trial (N=4,093) enrolled women with a mean femoral neck T-score of -2.96 [6]. In this cohort, a 12-month vertebral fracture rate of 6.2% was observed in the active comparator (alendronate) arm.

Now layer zolpidem use onto that baseline. The Berry et al. (2013) study of 34,163 nursing home residents found that new sedative-hypnotic use increased hip fracture risk by 66% within the first 15 days of prescribing (adjusted HR 1.66 to 95% CI 1.45 to 1.90) [7]. The risk was highest with zolpidem specifically, compared to other sedative classes.

These are not interacting mechanisms. They are additive vulnerabilities. A patient with a T-score of -3.0 who falls once at night due to zolpidem-induced impairment faces a substantially higher absolute fracture probability than a patient with normal bone density who takes the same fall.

Clinical Monitoring Protocol for Co-Administration

When both medications are clinically necessary, structured monitoring reduces harm. The American Geriatrics Society (AGS) Beers Criteria lists zolpidem as potentially inappropriate for adults 65 and older regardless of co-medications [8]. If the prescriber determines benefits outweigh risks, several steps minimize danger.

Dose limitation. The FDA revised zolpidem labeling in January 2013 to recommend 5 mg as the starting and maximum dose for women and older adults, down from the previous 10 mg, based on next-morning impairment data [2]. Patients on romosozumab should not exceed 5 mg immediate-release or 6.25 mg extended-release.

Timing assessment. Zolpidem's elimination half-life is 2.5 hours in healthy adults but extends to 2.9 hours in patients over 70 [2]. Next-morning residual sedation is the primary fall driver. Taking zolpidem only when 7 to 8 hours of sleep time remain before rising reduces, but does not eliminate, this window.

Fall prevention environment. Nightlights, non-slip flooring, removal of trip hazards, and bedside urinals or commodes reduce nocturnal fall events. A Cochrane review (Gillespie et al., 2012) found multifactorial fall interventions reduced fall rate by 24% (rate ratio 0.76 to 95% CI 0.67 to 0.86) in community-dwelling older adults [9].

DEXA and fracture monitoring. Standard romosozumab monitoring includes bone mineral density assessment at baseline and after the 12-month course. Adding a mid-course check at 6 months may be warranted if the patient reports any falls during treatment.

Alternatives to Zolpidem During the Romosozumab Course

Romosozumab treatment lasts exactly 12 months (12 once-monthly subcutaneous injections of 210 mg). This defined treatment window creates an opportunity to substitute lower-risk sleep interventions for the duration of the course.

Cognitive behavioral therapy for insomnia (CBT-I) is the first-line treatment for chronic insomnia per the American College of Physicians [10]. A 2015 meta-analysis showed CBT-I produced sustained sleep improvements at 12-month follow-up, while pharmacotherapy benefits disappeared after discontinuation [10]. Digital CBT-I platforms (Somryst/Pear Therapeutics received FDA clearance in 2020) provide accessible delivery.

Low-dose trazodone (25 to 50 mg) carries lower fall risk than Z-drugs in comparative observational studies, though it is not free of sedative effects. Trazodone does not appear on the AGS Beers Criteria at low doses.

Melatonin receptor agonists (ramelteon 8 mg) target the MT1/MT2 receptors without binding GABA-A. Ramelteon has no abuse potential and produces minimal next-day impairment [11]. It is less effective for sleep maintenance insomnia but suitable for sleep-onset difficulty.

Suvorexant or lemborexant (orexin receptor antagonists) showed lower fall rates than benzodiazepines in post-marketing data, though head-to-head trials against zolpidem in osteoporotic populations do not exist.

The key principle: any sedative carries some fall risk in a frail population. The goal is risk reduction, not zero risk, and the 12-month romosozumab window is a reasonable period to trial non-pharmacologic approaches.

Romosozumab's Cardiovascular Warning and Zolpidem's Cardiac Profile

Romosozumab carries a boxed warning for increased cardiovascular events. In the ARCH trial, major adverse cardiovascular events (MACE) occurred in 2.5% of romosozumab patients vs. 1.9% of alendronate patients over 12 months (HR 1.31 to 95% CI 0.85 to 2.00) [6]. The FDA restricts romosozumab use to patients without MI or stroke within the preceding year.

Zolpidem has no established cardiovascular toxicity at therapeutic doses. It does not prolong the QTc interval meaningfully. There is no additive cardiovascular interaction between these two agents. The romosozumab cardiovascular warning should be managed independently through blood pressure control, lipid management, and avoidance in patients with recent vascular events.

Special Populations: Renal and Hepatic Impairment

Romosozumab pharmacokinetics are unaffected by renal impairment. Because it is catabolized by proteolysis, neither creatinine clearance nor dialysis status alters its exposure [1]. No dose adjustment is required for any degree of renal dysfunction.

Zolpidem, however, requires caution in hepatic impairment. In patients with cirrhosis, the area under the curve (AUC) increased 5-fold and half-life extended to 9.9 hours compared to 2.5 hours in healthy volunteers [2]. The FDA recommends 5 mg in hepatic impairment and advises avoidance in severe hepatic insufficiency.

For a patient with both severe osteoporosis and liver disease receiving romosozumab, zolpidem becomes particularly problematic. The prolonged half-life amplifies next-morning impairment, and the fall risk window extends far beyond the normal 2 to 3 hour elimination period. Alternative sleep agents or non-pharmacologic approaches become strongly preferred in this scenario.

What Drug Interaction Databases Report

Major DDI checking systems (Lexicomp, Micromedex, Clinical Pharmacology) do not flag a romosozumab-zolpidem interaction as clinically significant. This is expected given the absence of shared metabolic pathways. However, most systems will generate a therapeutic duplication or additive-risk alert if both "fall risk" and "osteoporosis" flags are active in the patient record.

Prescribers should interpret the lack of a formal DDI flag correctly: it means plasma drug levels are unaffected. It does not mean co-prescribing is without consequence. The FRAME and ARCH trial populations were not specifically analyzed for sedative-hypnotic co-use, so controlled data on fracture outcomes with concurrent zolpidem are unavailable [5][6].

Patient Counseling Points

Patients receiving both medications need three specific instructions. First, take zolpidem only immediately before getting into bed with 7 to 8 hours of planned sleep remaining. Do not take it and then perform activities. Second, if you wake during the night, sit on the edge of the bed for 30 seconds before standing, use handrails, and keep the path to the bathroom lit. Third, report any falls, near-falls, or episodes of doing activities you do not remember to your prescriber immediately. A single fall during romosozumab therapy may prompt reassessment of the sleep medication.

The American Academy of Orthopaedic Surgeons recommends that all patients on osteoporosis treatment receive fall prevention counseling at each visit [12]. This recommendation carries even greater weight when concurrent sedative-hypnotic use is present.